{"preliminary_commentary":{"by_channel":{"youtube":4,"podcast":3,"x_thread":1},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04468984\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["navitoclax","ruxolitinib"],["navitoclax"]],"indication":"relapsed/refractory myelofibrosis","name":"TRANSFORM-2","nct_id":"NCT04468984","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=transform-2-nct04468984. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"TRANSFORM-2","arms":[{"description":"Participants will receive navitoclax tablets once daily and ruxolitinib tablets twice daily.","label":"Arm A: Navitoclax + Ruxolitinib","type":"EXPERIMENTAL"},{"description":"Participants will receive one of the BAT options, per the investigator's discretion.","label":"Arm B: Best Available Therapy (BAT)","type":"ACTIVE_COMPARATOR"},{"description":"Participants will receive navitoclax tablets once daily.","label":"Arm C: Continued Access for Navitoclax","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2026-12","type":"ESTIMATED"},"conditions":["Myelofibrosis (MF)"],"enrollment":{"count":330,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Navitoclax","otherNames":[],"type":"DRUG"},{"name":"Ruxolitinib","otherNames":[],"type":"DRUG"},{"name":"Best Available Therapy (BAT)","otherNames":[],"type":"DRUG"}],"last_update":"2026-01-09","lead_sponsor":"AbbVie","official_title":"Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed/Refractory Myelofibrosis (TRANSFORM-2), Incorporating Extension Arm C - Continued Access for Navitoclax to Roll Over Subjects From Studies M10-166, M16-109, M16-191, and M19-753","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2025-01-29","type":"ACTUAL"},"primary_outcomes":[{"measure":"Arms A and B: Percentage of Participants who achieve Spleen Volume Reduction of at least 35% at Week 24 (SVR35W24)","timeFrame":"At Week 24"}],"references":[{"citation":"Rampal RK, Harrison CN, Mesa R, Vannucchi AM, Shimoda K, Perkins A, Garcia JS, Reiter A, Radinoff A, Pane F, Palandri F, Lomaia E, Lee SE, Chuah HS, Passamonti F, Saydam G, Turgut M, Yoon SS, Bain EE, Lam H, Jain S, Potluri J, Kiladjian JJ. Navitoclax monotherapy or in combination with ruxolitinib in patients with JAK2 inhibitor-treated myelofibrosis: results from the phase 2 REFINE and phase 3 TRANSFORM-2 studies. Leuk Lymphoma. 2026 Oct 7:1-11. doi: 10.1080/10428194.2026.2739358. Online ahead of print.","pmid":"42842696","type":"DERIVED"}],"start_date":{"date":"2020-08-31","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"Study of Oral Navitoclax Tablet in Combination With Oral Ruxolitinib Tablet Versus Best Available Therapy to Assess Change in Spleen Volume in Adult Participants With Relapsed/Refractory Myelofibrosis","url":"https://clinicaltrials.gov/study/NCT04468984"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.1","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/transform-2-nct04468984"}